Myofascial Trigger Points: Does the Injectate Matter, or Just the Needle?
Meta-analytic evidence suggests the needle itself, not what's injected through it, may be doing most of the work in myofascial trigger-point therapy. The disagreement here is whether that finding should change what gets offered first.
Renata O., a 52-year-old accountant who spends most of her workday hunched over dual monitors, has had a deep, aching pain across her right upper trapezius and levator scapulae for six months, radiating up toward her ear on bad days and occasionally waking her when she rolls onto that side at night. Exam finds a discrete taut band in the upper trapezius with a reproducible local twitch response on palpation and clear referred pain matching her own description — a textbook myofascial trigger point, not the diffuse tenderness of fibromyalgia she was initially told she might have when a colleague suggested the same symptoms. She has completed eight weeks of physical therapy focused on postural correction and stretching, plus a trial of scheduled NSAIDs, with only modest and temporary relief, and has recently switched to a standing desk on her own initiative without any real change in her symptoms either way.
The question in front of the team is what to actually inject, if anything, once a needle goes into that band — and the evidence here cuts against the assumption that the drug does the work. Cummings and White's 2001 systematic review compared trigger-point injections using an active substance (typically local anesthetic) against dry needling with no injectate at all, across the available randomized trials, and found no significant difference in outcome between the two — the mechanical disruption of the taut band and its local twitch response appears to be the more important variable than what, if anything, accompanies the needle. Botulinum toxin has been tested as a step up from both: Ferrante and colleagues' 2005 randomized trial compared BoNT injection directly against saline injection in myofascial pain and found no significant difference between them, a genuinely disappointing result for a drug whose neuromuscular-junction-blocking mechanism seems, on paper, like it should outlast a local anesthetic's effect considerably. Her own strong preference, stated at the start of today's visit, is to avoid an unnecessary injectate if the needle placement itself is likely to do the same job.
Physiatry consult, six months of neck and shoulder pain
I'd start with dry needling alone. Cummings and White's 2001 systematic review pooled the available randomized comparisons of wet injection against dry needling for myofascial trigger points and found no significant difference between them — the local twitch response and the mechanical disruption of the taut band appear to be doing the real work, not the injectate itself. She's told us directly she'd rather avoid an unnecessary substance if the needle placement alone is likely to do the same job, and the evidence doesn't ask her to give anything up by choosing that.
I agree with the meta-analysis as a description of the average outcome across trials, and I'm not proposing we override her stated preference lightly.
But an average null result across pooled trials doesn't mean every individual patient experiences the two approaches identically. She's told us she has some needle-related anxiety, and a local anesthetic gives a fast, tangible reduction in periprocedural discomfort that a dry needle alone doesn't — a real benefit even if it isn't the one the meta-analysis was designed to measure.
Whatever we decide between those two, I don't think botulinum toxin belongs in this conversation as a first option for either of you to fall back on. Ferrante and colleagues ran a direct randomized comparison of BoNT against saline injection in 2005 in myofascial pain and found no significant difference — a genuinely negative result for a drug that, mechanistically, should last longer than either of the options you're discussing.
I'd hold it out of today's plan entirely and revisit only if dry needling, and if needed local anesthetic, both fail to help her.
Dry needling performed today at the identified trigger point, with local anesthetic infiltration offered but declined by the patient once she understood the evidence didn't favor it. Follow-up in three weeks to assess response before considering repeat treatment.